ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b) On September 29, 2020, Dr. Andrew Satlin notified Intra-Cellular Therapies,
Inc. (the "Company") that he would resign from his position as Chief Medical
Officer of the Company effective as of October 28, 2020 in order to pursue a new
opportunity. Dr. Satlin will assist with the transition of his responsibilities
through October 28, 2020. Dr. Satlin's resignation was not the result of any
disagreement with the Company or its Board of Directors on any matter relating
to the Company's operations, policies or practices.
ITEM 8.01 Other Events.
On October 1, 2020, the Company announced its promotion of Suresh K. Durgam,
M.D. to the position of Chief Medical Officer of the Company. Dr. Durgam has
served as the Company's Senior Vice President, Late Stage Clinical Development
and Medical Affairs since joining the Company in August 2018.
A copy of the press release announcing Dr. Durgam's promotion is attached hereto
as Exhibit 99.1.
ITEM 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release of Intra-Cellular Therapies, Inc., dated October 1,
2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses